U.S. Markets closed
  • S&P 500

    4,577.11
    -85.74 (-1.84%)
     
  • Dow 30

    35,368.47
    -543.34 (-1.51%)
     
  • Nasdaq

    14,506.90
    -386.86 (-2.60%)
     
  • Russell 2000

    2,096.23
    -66.23 (-3.06%)
     
  • Crude Oil

    86.80
    +1.37 (+1.60%)
     
  • Gold

    1,813.90
    +1.50 (+0.08%)
     
  • Silver

    23.51
    +0.02 (+0.10%)
     
  • EUR/USD

    1.1329
    -0.0081 (-0.7137%)
     
  • 10-Yr Bond

    1.8650
    +0.0930 (+5.25%)
     
  • Vix

    22.79
    +3.60 (+18.76%)
     
  • GBP/USD

    1.3598
    -0.0049 (-0.3576%)
     
  • USD/JPY

    114.6300
    +0.0500 (+0.0436%)
     
  • BTC-USD

    42,356.97
    +109.06 (+0.26%)
     
  • CMC Crypto 200

    1,009.15
    -0.24 (-0.02%)
     
  • FTSE 100

    7,563.55
    -47.68 (-0.63%)
     
  • Nikkei 225

    28,257.25
    0.00 (0.00%)
     

Biocept to Present at the LD Micro Main Event on October 13

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SAN DIEGO, October 06, 2021--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present a company overview at the LD Micro Main Event on Wednesday, October 13, 2021 at 11:00 a.m. Pacific time (2:00 p.m. Eastern time). The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles.

A pre-recorded webcast of the presentation will be available on the Events and Presentations page of the company website beginning October 13 at 11:00 a.m. Pacific time.

About Biocept

Biocept, Inc., develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information to aid in the diagnosis, treatment and monitoring of patients with cancer. In addition to its broad portfolio of blood-based liquid biopsy tests, the company has developed the CNSideTM cerebrospinal fluid assay, designed to diagnose cancer that has metastasized to the central nervous system. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide RT-PCR-based COVID-19 testing and services to support public health efforts during this unprecedented pandemic. For more information, visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211006005352/en/

Contacts

Investors
Jody Cain, LHA Investor Relations
Jcain@lhai.com, 310-691-7100

Media
Andrea Sampson, Sampson PR Group
asampson@sampsonprgroup.com, 562-304-0301